

# Christophe Willekens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2305721/publications.pdf>

Version: 2024-02-01

16  
papers

3,706  
citations

759190

12  
h-index

940516

16  
g-index

16  
all docs

16  
docs citations

16  
times ranked

6590  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. <i>Leukemia and Lymphoma</i> , 2021, 62, 438-445.	1.3	5
2	<i>ATG2B/GSKIP</i> in <i>de novo</i> acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1770-1773.	1.3	5
3	Severe COVID-19 in patients with hematological cancers presenting with viremia. <i>Annals of Oncology</i> , 2021, 32, 1297-1300.	1.2	14
4	First-in-Human Phase I Study of ladademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 4260-4273.	1.6	59
5	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 421-428.	0.7	3
6	Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> , 2020, 182, 1401-1418.e18.	28.9	663
7	Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia. <i>Blood</i> , 2019, 134, 2414-2416.	1.4	14
8	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of <i>IDH1/2</i> mutations. <i>Leukemia</i> , 2018, 32, 2008-2081.	7.2	18
9	ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. <i>Cancer Cell</i> , 2018, 33, 495-511.e12.	16.8	216
10	A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset. <i>Nature Communications</i> , 2018, 9, 5455.	12.8	33
11	Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
12	Clonal heterogeneity of acute myeloid leukemia treated with the <i>IDH2</i> inhibitor enasidenib. <i>Nature Medicine</i> , 2018, 24, 1167-1177.	30.7	157
13	Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
14	Engraftment of chronic myelomonocytic leukemia cells in immunocompromised mice supports disease dependency on cytokines. <i>Blood Advances</i> , 2017, 1, 972-979.	5.2	25
15	Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 3618-3626.	1.4	197
16	Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. <i>European Journal of Cancer</i> , 2015, 51, 2386-2395.	2.8	32